Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases in addition to other liver and gastrointestinal (GI) diseases. Its clinical pipeline includes two Phase II candidates and one Phase III candidate. Its lead product candidate, A4250, is currently being studied in a Phase II clinical trial in children with cholestatic liver disease that is designed to support Albireo’s planned future pivotal development in progressive familial intrahepatic cholestatasis (PFIC). A4250 is currently on track to initiate this pivotal Phase III trial in 2H-2017. In addition to PFIC, Albireo is planning to develop A4250 in other rare pediatric cholestatic diseases such as Alagille syndrome, biliary atresia and mixed cholestasis. Further, the Company is developing Elobixibat, which is in Phase III development for chronic idiopathic constipation (CIC).